Names | |
---|---|
Preferred IUPAC name 5--2H-pyranopyrimidine-2,4,7(1H,3H)-trione | |
Identifiers | |
CAS Number | |
3D model (JSmol) | |
ChEMBL | |
ChemSpider | |
DrugBank | |
PubChem CID | |
UNII | |
CompTox Dashboard (EPA) | |
InChI
| |
SMILES
| |
Properties | |
Chemical formula | C14H16N2O4 |
Molar mass | 276.292 g·mol |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C , 100 kPa). Infobox references |
SCH 900271 is a nicotinic acid derivative designed to treat dyslipidemia. It reduced plasma free fatty acids levels, but without significant flushing, a side effect common with niacin that limits its usefulness. SCH 900271 is currently in human trials.
References
- Palani, Anandan (November 2011). "Discovery of SCH 900271, a Potent Nicotinic Acid Receptor Agonist for the Treatment of Dyslipidemia". ACS Medicinal Chemistry Letters. 3 (1): 63–8. doi:10.1021/ml200243g. PMC 4025820. PMID 24900372.
This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it. |